Alx Oncology Holdings Inc (ALXO) Stock Analysis and Metrics

Alx Oncology Holdings

NASDAQ: ALXO

$2.03 ▲ +0.01 (+0.50%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap213.33 Mn

P/E-2.22

Div. Yield0.00

Total Debt (Qtr)8.51 Mn

Add ratio to table…

About

Alx Oncology Holdings Inc is a clinical stage biotechnology company focused on developing novel therapies for cancer. The company's lead product candidate is evorpacept a CD47 blocking fusion protein designed to be used in combination with anti cancer antibodies. Its second candidate is ALX2004 an EGFR targeted antibody drug conjugate currently being evaluated in a first in human clinical trial. Alx Oncology Holdings Inc aims to advance these candidates through clinical development with the goal of providing new treatment options for patients with solid tumors and hematologic malignancies. The firm operates from its headquarters in the United States and relies on external partners for manufacturing and clinical trial execution.

Alx Oncology Holdings Inc generates revenue primarily through collaboration and licensing agreements with pharmaceutical and academic partners. These agreements typically involve upfront payments milestone payments and royalties on net sales of any future approved products. The company has a collaboration with Jazz Pharmaceuticals to develop evorpacept in combination with the HER2 targeted bispecific zanidatamab. Another collaboration with Sanofi focuses on evorpacept together with the CD38 targeted antibody isatuximab for the treatment of multiple myeloma. Alx Oncology Holdings Inc also works with MD Anderson Cancer Center on an investigator sponsored trial of evorpacept with rituximab for non Hodgkin lymphoma. The license agreement with Stanford University provides potential milestone payments and low single digit royalties on net sales of evorpacept and related products. The company anticipates that commercial scale manufacturing will be managed by contract manufacturing organizations.

Alx Oncology Holdings Inc positions itself as a developer of next generation immuno oncology therapies with a focus on CD47 blockade and EGFR targeting. The company's lead candidate evorpacept is designed to overcome the hematologic toxicities seen with other CD47 blocking agents that rely on an active Fc region. Evorpacept's inactive Fc domain aims to provide a broader therapeutic window and enable combination with a wide range of anti cancer antibodies chemotherapy and checkpoint inhibitors. The second candidate ALX2004 seeks to address limitations of earlier EGFR targeted antibody drug conjugate approaches by using a topoisomerase I inhibitor payload and a matuzumab derived antibody to reduce off tumor toxicity. Competitors in the CD47 space include Gilead Sciences through its acquisition of Forty Seven Pfizer through its acquisition of Trillium Therapeutics and various other biotechnology firms. In the EGFR targeted antibody drug conjugate arena competitors include AstraZeneca Daiichi Sankyo and several academic research programs. Alx Oncology Holdings Inc believes its differentiation lies in the engineered binding affinity of evorpacept the inactive Fc design and the payload selection of ALX2004 which together may provide improved efficacy and safety.

Alx Oncology Holdings Inc's eventual customers are expected to be patients receiving oncology treatment and the healthcare providers that administer those therapies. These include hospitals outpatient clinics and specialty cancer centers. The company also works with pharmaceutical partners through collaboration agreements which may become customers if its product candidates achieve regulatory approval. Revenue from product sales will depend on the ability to meet the needs of these patient populations and healthcare systems.

Investment Thesis

▲ Bull case

ALXO's evorpacept demonstrates transformative potential in heavily pretreated HER2-positive metastatic breast cancer patients with high CD47 expression, achieving a 100% objective response rate, median duration of response of 20.2 months, and median progression-free survival of 22.1 months in the zanidatamab combination study, significantly outperforming the historical benchmark of less than 6 months PFS post-T-DXd treatment and validating the biomarker-driven approach as a critical differentiator in a crowded oncology landscape where immuno-oncology options remain scarce after antibody-drug conjugate failure.
The ongoing ASPEN-09 Phase II trial, designed to enroll 120 patients with interim data expected from approximately 80 patients by mid-2027, is positioned to deliver statistically robust validation of the CD47-high patient subset, with management indicating that a 30% objective response rate would represent a doubling of historical outcomes and serve as a compelling catalyst for potential accelerated approval discussions, particularly given the trial's focus on the post-ENHERTU setting where no IO therapies are currently approved and the mechanistic rationale for evorpacept is strongly supported by preclinical and clinical data across two independent HER2-positive indications.
ALX2004, ALXO's novel EGFR-targeted antibody-drug conjugate, is advancing steadily through Phase I dose escalation with plans for initial safety readout in the second half of 2026, leveraging a differentiated epitope and linker-payload construct designed to overcome historical challenges in EGFR-targeted ADCs, including off-tumor toxicity and resistance, while preclinical data translating to clinical tolerability and the ability to escalate doses suggest a favorable therapeutic index that could unlock significant value in EGFR-expressing cancers such as lung, head and neck, colorectal, and esophageal malignancies, where high unmet need exists despite EGFR's validation as a target.
The company's strengthened balance sheet following a February financing round anchored by strong institutional investors provides sufficient capital to execute through key clinical milestones over the next 12–18 months without dilution concerns, enabling uninterrupted advancement of both evorpacept and ALX2004 programs toward registrational readiness by end of next year, while the addition of Jeff Knight as Chief Development and Chief Operating Officer—cited as one of the best operators in biotech for building companies through commercialization—adds critical execution expertise that is often underappreciated in early-stage biotech but vital for navigating complex development and potential commercial pathways.

ALXO's evorpacept demonstrates transformative potential in heavily pretreated HER2-positive metastatic breast cancer patients with high CD47 expression, achieving a 100% objective response rate, median duration of response of 20.2 months, and median progression-free survival of 22.1 months in the zanidatamab combination study, significantly outperforming the historical benchmark of less than 6 months PFS post-T-DXd treatment and validating the biomarker-driven approach as a critical differentiator in a crowded oncology landscape where immuno-oncology options remain scarce after antibody-drug conjugate failure.
The ongoing ASPEN-09 Phase II trial, designed to enroll 120 patients with interim data expected from approximately 80 patients by mid-2027, is positioned to deliver statistically robust validation of the CD47-high patient subset, with management indicating that a 30% objective response rate would represent a doubling of historical outcomes and serve as a compelling catalyst for potential accelerated approval discussions, particularly given the trial's focus on the post-ENHERTU setting where no IO therapies are currently approved and the mechanistic rationale for evorpacept is strongly supported by preclinical and clinical data across two independent HER2-positive indications.
ALX2004, ALXO's novel EGFR-targeted antibody-drug conjugate, is advancing steadily through Phase I dose escalation with plans for initial safety readout in the second half of 2026, leveraging a differentiated epitope and linker-payload construct designed to overcome historical challenges in EGFR-targeted ADCs, including off-tumor toxicity and resistance, while preclinical data translating to clinical tolerability and the ability to escalate doses suggest a favorable therapeutic index that could unlock significant value in EGFR-expressing cancers such as lung, head and neck, colorectal, and esophageal malignancies, where high unmet need exists despite EGFR's validation as a target.
The company's strengthened balance sheet following a February financing round anchored by strong institutional investors provides sufficient capital to execute through key clinical milestones over the next 12–18 months without dilution concerns, enabling uninterrupted advancement of both evorpacept and ALX2004 programs toward registrational readiness by end of next year, while the addition of Jeff Knight as Chief Development and Chief Operating Officer—cited as one of the best operators in biotech for building companies through commercialization—adds critical execution expertise that is often underappreciated in early-stage biotech but vital for navigating complex development and potential commercial pathways.

▼ Bear case

ALXO's evorpacept data, while promising, remains based on extremely small sample sizes—particularly the CD47-high subset in the zanidatamab combination study, which included only five patients with centrally confirmed HER2-positive disease—raising significant concerns about the durability and generalizability of the observed 100% response rate, 20.2-month duration of response, and 22.1-month median PFS, especially given the exploratory nature of the biomarker analysis and the lack of randomization or control arm, which limits the ability to attribute outcomes solely to the drug combination amidst heavy pretreatment and potential confounding factors from prior therapies.
The company's reliance on CD47 expression as a predictive biomarker introduces substantial execution risk, as the optimal cutoff for patient selection remains undefined and varies across tumor types—evident in the discrepancy between the 20% IHC threshold used in the breast study and the historically referenced 10% IHC 3+ cutoff for gastric cancer—while ongoing ASPEN-09 enrollment does not stratify by CD47 status, delaying critical biomarker validation until mid-2027 and creating uncertainty about whether the addressed population of 20,000 CD47-high HER2-positive patients in the U.S., Europe, and Japan is accurate or overstated, potentially undermining the $2 billion to $4 billion market opportunity thesis if real-world prevalence proves lower.
ALX2004's clinical progress, while described as on track, lacks meaningful efficacy or pharmacokinetic data beyond dose escalation, with no disclosure of objective response rates, disease control rates, or signals of antitumor activity in the ongoing Phase I trial for EGFR-expressing cancers, increasing the risk that the molecule may fail to overcome historical obstacles in EGFR-targeted ADCs such as on-target toxicity (despite the engineered antibody selection), inadequate payload delivery, or rapid resistance development, particularly given EGFR's heterogeneity and the competitive landscape of established and emerging ADC and tyrosine kinase inhibitor therapies in lung and gastrointestinal malignancies.
Despite management's confidence in avoiding accelerated approval hurdles, the regulatory path for evorpacept in HER2-positive breast cancer remains steep, as single-arm trials with combination therapies face significant skepticism from the FDA—especially when reliant on a companion diagnostic for patient selection—and the absence of a clear plan for prospective validation of the CD47 biomarker in the pivotal trial setting, coupled with the acknowledgment that even a north-of-30% response rate in ASPEN-09 would require an uphill battle for approval, heightens the risk that the company may be forced into a larger, more expensive, and time-consuming Phase III trial, straining resources and delaying potential commercialization beyond current expectations.

ALXO's evorpacept data, while promising, remains based on extremely small sample sizes—particularly the CD47-high subset in the zanidatamab combination study, which included only five patients with centrally confirmed HER2-positive disease—raising significant concerns about the durability and generalizability of the observed 100% response rate, 20.2-month duration of response, and 22.1-month median PFS, especially given the exploratory nature of the biomarker analysis and the lack of randomization or control arm, which limits the ability to attribute outcomes solely to the drug combination amidst heavy pretreatment and potential confounding factors from prior therapies.
The company's reliance on CD47 expression as a predictive biomarker introduces substantial execution risk, as the optimal cutoff for patient selection remains undefined and varies across tumor types—evident in the discrepancy between the 20% IHC threshold used in the breast study and the historically referenced 10% IHC 3+ cutoff for gastric cancer—while ongoing ASPEN-09 enrollment does not stratify by CD47 status, delaying critical biomarker validation until mid-2027 and creating uncertainty about whether the addressed population of 20,000 CD47-high HER2-positive patients in the U.S., Europe, and Japan is accurate or overstated, potentially undermining the $2 billion to $4 billion market opportunity thesis if real-world prevalence proves lower.
ALX2004's clinical progress, while described as on track, lacks meaningful efficacy or pharmacokinetic data beyond dose escalation, with no disclosure of objective response rates, disease control rates, or signals of antitumor activity in the ongoing Phase I trial for EGFR-expressing cancers, increasing the risk that the molecule may fail to overcome historical obstacles in EGFR-targeted ADCs such as on-target toxicity (despite the engineered antibody selection), inadequate payload delivery, or rapid resistance development, particularly given EGFR's heterogeneity and the competitive landscape of established and emerging ADC and tyrosine kinase inhibitor therapies in lung and gastrointestinal malignancies.
Despite management's confidence in avoiding accelerated approval hurdles, the regulatory path for evorpacept in HER2-positive breast cancer remains steep, as single-arm trials with combination therapies face significant skepticism from the FDA—especially when reliant on a companion diagnostic for patient selection—and the absence of a clear plan for prospective validation of the CD47 biomarker in the pivotal trial setting, coupled with the acknowledgment that even a north-of-30% response rate in ASPEN-09 would require an uphill battle for approval, heightens the risk that the company may be forced into a larger, more expensive, and time-consuming Phase III trial, straining resources and delaying potential commercialization beyond current expectations.

Related Party Breakdown of Revenue (2020)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Related Party Breakdown of Revenue (2020)

Related Party Breakdown of Revenue (2020)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Related Party Breakdown of Revenue (2020)

Related Party Breakdown of Revenue (2020)

Peer Comparison

Create an account

Sign In

Reset Password